期刊文献+

他达拉非治疗勃起功能障碍:卓越的36小时疗效 被引量:3

Tadalafil for Erectile Dysfunction:Outstanding Efficacy for 36 Hours
原文传递
导出
摘要 磷酸二酯酶5(PDE5)抑制剂是治疗勃起功能障碍(ED)的一线口服药物,与其他两种PDE5抑制剂(西地那非和伐地那非)相比,他达拉非有着起效快、服用方便和疗效显著的特点,但更为突出的是其较长的血浆清除半衰期带来的36h的持续药效,可以使患者和伴侣能更加自由地安排用药时间。患者和伴侣对他达拉非治疗的高满意度可能主要源于对用药时间顾虑的减少和对性生活时程关注度下降等社会心理收益。同时,他达拉非的安全性和耐受性良好,符合安全、有效、方便的用药原则,使其成为大多数ED患者及其伴侣偏爱的首选用药。 Phosphodiesterase type 5 ( PDE5 ) inhibitors are first-line oral medication for erectile dysfunction (ED). Compared with the other two PDE inhibitors (sildenafil and vardenafil), tadalafil is characterized by rapid onset, convenient dosing, excellent efficacy, especially the 36-hour duration of effectiveness deriving from long elimination half-life, allowing for more flexibility to scheduled medication. Higher satisfaction of patients and their partners with tadalafil is mainly due to such psychosocial benefits as decreased time concerns. Tadalafil is well-tolerated, consistent with the principle of safely, effectiveness and convenient dosing and is becoming the favorite choice of ED patients and their partners.
作者 邓庶民
出处 《中华男科学杂志》 CAS CSCD 2008年第9期857-860,共4页 National Journal of Andrology
关键词 磷酸二酯酶5抑制剂 勃起功能障碍 他达拉非 疗效 phosphocliesterase type 5 erectile dysfunction tadalafil efficacy
  • 相关文献

参考文献21

  • 1McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction [ J]. Int J Impot Res, 2000, 12 Suppl 4 (12) : S6-11.
  • 2Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences[ J]. Br J Urol Int, 1999, 84( 1 ) : 50-56.
  • 3Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors[J]. Int J Clin Pract, 2002, 56(6) :453-459.
  • 4Viagra (sildenafil) (package insert). New York, N. Y. : Pfizer Inc. , 2002.
  • 5Levitra (vardenafil) ( package insert). New Haven, Conn. : Bayer Pharmaceuticals Corp. , 2003.
  • 6Cialis (tadalatil) ( package insert). Indianapolis, Ind. : Lilly ICOS LLC; 2003.
  • 7Nusbaum MR. Therapeutic options for patients returning to sexual activity[J]. J Am Osteopath Assoc, 2004, 104(3 Supple 4) : S2-5.
  • 8Marumo A, Imaoka T, Fujimoto K, et al. A comparison of the efficacy and tolerability of tadalafil 10 mg and 20 mg in Japanese patients with severe erectile dysfunction[ J]. J Sex Med, 2007,4 (3) : 745-752.
  • 9Supuran CT, Mastrolorenzo A, Barbaro G, et al. Phosphodiesterase 5 inhibitors - drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles [ J ]. Curr Pharm Des, 2006, 12(27): 3459-3465.
  • 10Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction : results of integrated analyses[ J]. J Urol, 2002, 168 (4 Pt 1 ) : 1332-1336.

同被引文献14

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部